BET inhibitor resistance emerges from leukaemia stem cells
Targeting the bromodomains of BET family proteins has emerged as one of the most promising epigenetic therapies in a variety of cancers. In this report, which started in the Huntly lab, Chun et al. report mechanisms of drug resistance to these inhibitors. This information can be utilised in the clinic, allowing combination treatment strategies in order to improve clinical outcomes. Read more in Nature.